Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Columbus, Ohio 43210


The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.


Inclusion Criteria: - Proven breast cancer - Metastatic or locally advanced breast cancer - Hormonally responsive disease defined as estrogen (ER) and/ or progesterone receptor (PR) positive (>10% staining by immunohistochemistry) - Postmenopausal status - No more than 1 prior chemotherapy for stage IV metastatic breast cancer allowed - ECOG (Eastern Cooperative Oncology Group) performance status 0-2 - Adequate organ function - Exclusion Criteria: - No prior Exemestane or Fulvestrant - Uncontrolled intercurrent illness including but not limited to: - ongoing or active infection - symptomatic congestive heart failure - unstable angina pectoris - cardiac arrhythmia - myocardial infarction within the last 3 months - psychiatric illness/social situations that would limit compliance with study - Lymphangitic pulmonary disease; carcinomatous meningitis, bone marrow only metastases; and a rising tumor marker without any other site of metastatic disease. - Presence of bleeding diathesis or coagulopathy, patients requiring coumadin



Primary Contact:

Principal Investigator
Ewa Mrozek, MD
Ohio State University

Backup Contact:


Location Contact:

Columbus, Ohio 43210
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.